Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
IPO Year: 2006
Exchange: NASDAQ
Website: catalystbiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2021 | Outperform → Market Perform | Raymond James | |
| 8/6/2021 | $19.00 → $18.00 | Outperform | Raymond James |
8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K/A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K/A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
RW - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
D - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
S-3 - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data. "We are thrilled by Nassim's arrival," said DCVC Bio Managing Pa
Reiterates the Board's Commitment to Expeditiously Distributing All of the Company's Available Cash to Stockholders, Net of Liabilities and Obligations Warns Stockholders that JDS1 May Have Ulterior Motives in Running a Proxy Contest: Gaining Control of the Company's Cash and Other Assets for JDS1's Own Benefit Stockholders Urged to VOTE "FOR" ALL of Catalyst's Nominees, Who Are Committed to the Company's Cash Distribution Plan, on the WHITE Proxy Card SOUTH SAN FRANCISCO, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the "Company" or "we") today announced that it mailed a letter to its stockholders in connection with the Company's upcoming 2022 Ann
ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company's board of directors. Ms. Tetlow will also serve as chair of the audit committee. "On behalf of the board and management team at ShouTi, I am pleased to welcome Sharon to the board," said Daniel Welch, Chairman of the Board, ShouTi. "Sharon is an accomplished life sciences finance executive whose deep financial strategy and compliance expertise will be instrumental in leading our audit committee. With an outstanding track record of advising biopharmaceutical companies, Sharon's perspectiv
Seasoned Biopharmaceutical Executive Adds Substantial Corporate Development Expertise SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced the appointment of Jeanne Jew to its Board of Directors. "We are delighted to welcome Jeanne to our Board of Directors. Jeanne's deep corporate development expertise will be a tremendous asset as we advance our Protease Medicines pipeline," said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. Ms. Jew commented, "I look forward to supporting the company's continued growth and working with the team on its strategic planning and business development initiatives.
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
3/A - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data. "We are thrilled by Nassim's arrival," said DCVC Bio Managing Pa
The combined company will operate as "Gyre Therapeutics, Inc." with its common stock traded on Nasdaq under trading symbol "GYRE" effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst") today announced completion of the business combination with GNI Group Ltd. and related entities. Catalyst received stockholder approval for all proposals necessary to complete the business combination at a special meeting of stockholders held on August 29, 2023. Catalyst effected a name change and a reverse stock split of Catalyst's common stock immediately prior to the closing of the business combination. The combined company w
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ:CBIO) ("Catalyst" or "the Company") today provided two corporate updates. In connection with the Company's previously announced asset purchase agreement with GNI Group Ltd ("GNI Group") and GNI Hong Kong Limited (together "GNI") to purchase all of the assets and intellectual property rights primarily related to GNI's proprietary hydronidone compound outside of China (collectively, the "F351 Assets"), and the definitive agreement with GNI and other minority stockholders to purchase their controlling interest in Beijing Continent Pharmaceutical Co. Ltd., a commercial-stage pharmaceutical company
Entered into an acquisition deal of 3 programsYONGIN, South Korea, Feb. 27, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ:CBIO) to acquire 3 programs related to the orphan hematology disorders. This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog alfa (MarzAA)", an engineered factor VIIa which is ready for Phase 3 clinical stage development. In its previous clinical development trials, "
Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst") and GNI Group Ltd. (2160.T) ("GNI") today announced that the parties have signed definitive agreements for the sale and purchase of GNI's proprietary new chemical entity F351 program. F351 has shown clinical efficac
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Stockholders of record on the record date who sell their shares prior to the ex-dividend date will not receive the special dividend. The aggregate amount of the payment to be made in connection with this special dividend will be app
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million. The Company anticipates that it may declare one or more additional special dividends in the future, although there can be no assurance that such distributions will
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that JDS1, LLC, one of the Company's stockholders, has dismissed its lawsuits against the Company. "With the JDS1 litigation behind us, the Board of Directors will be meeting to determine the details of an initial distribution of capital, and we will communicate this information to shareholders shortly," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. In addition to dismissing its lawsuits against the Company, JDS1 and certain of its affiliates have agreed to a customary standstill and voting commitment, and
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the "Company" or "we") today announced its operating and financial results for the second quarter ended June 30, 2022. "We were very pleased to have completed the sale of our complement portfolio during the second quarter to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ("Vertex") for $60.0 million in cash with up to $5.0 million of that amount due in May 2023. This transaction was the result of a comprehensive and competitive review of strategic alternatives led by the Company's Board of Directors (the "Board"), management team and independent legal and financial advisors," said N
JDS1, LLC ("JDS1"), which collectively with the other reporting persons in its Section 13(d) group, beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst" or the "Company"), commented today on its previously announced withdrawal of the director nominations and other proposed business that it had intended to bring before the upcoming 2022 Annual Meeting of Stockholders of Catalyst Biosciences, Inc. As previously disclosed last week in its public filings with the Securities and Exchange Commission, JDS1 has withdrawn its nominations of candidates for election to the Catalyst Board of Directors at Catalyst's Annual Meeti
SC 13G/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)
SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)
SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)
SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)
SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)
SC 13G/A - CATALYST BIOSCIENCES, INC. (0001124105) (Subject)
SC 13G/A - CATALYST BIOSCIENCES, INC. (0001124105) (Subject)
SC 13G/A - CATALYST BIOSCIENCES, INC. (0001124105) (Subject)
SC 13G/A - CATALYST BIOSCIENCES, INC. (0001124105) (Subject)
SC 13D/A - CATALYST BIOSCIENCES, INC. (0001124105) (Subject)
Raymond James downgraded Catalyst Biosciences from Outperform to Market Perform
Raymond James reiterated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $18.00 from $19.00 previously
Stephens resumed coverage of Catalyst Biosciences with a rating of Overweight and set a new price target of $19.00 from $18.00 previously
Raymond James reiterated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $19.00 from $18.00 previously
Raymond James initiated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $18.00
Piper Sandler initiated coverage of Catalyst Biosciences with a rating of Overweight and set a new price target of $15.00
Raymond James reiterated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $18.00 from $20.00 previously
Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst") and GNI Group Ltd. (2160.T) ("GNI") today announced that the parties have signed definitive agreements for the sale and purchase of GNI's proprietary new chemical entity F351 program. F351 has shown clinical efficac
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Stockholders of record on the record date who sell their shares prior to the ex-dividend date will not receive the special dividend. The aggregate amount of the payment to be made in connection with this special dividend will be app
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million. The Company anticipates that it may declare one or more additional special dividends in the future, although there can be no assurance that such distributions will
Company to discontinue MarzAA development; focus on developing its complement portfolio Management to host a call today at 8:30 am ET SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced a strategic decision to halt the clinical development of MarzAA, report data to date, and seek a buyer for its hemophilia assets. Catalyst plans to focus its resources on its complement therapeutics and protease medicines platform. The Company also reported its operating and financial results for the third quarter ended September 30, 2021. "We have made a strategic decision to stop the clinical development of MarzAA (engineered FVIIa) an
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with Hemophilia A or B with inhibitors that will enter a pivotal Phase 3 study CRIMSON 1 this month. The Fast Track program is designed to facilitate and expedite the development and review of drug candidates that have demonstrated the potential to address an unmet medical need in treating ser
Gainers TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 16.7% to $0.42 during Monday's after-market session. Today's trading volume for this security ended up closing at 3.7 million shares, which is 69.6 percent of its average volume over the last 100 days. The company's market cap stands at $5.0 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 16.23% to $0.54. This security traded at a volume of 96.0K shares come close, making up 67.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $8.6 million. Artelo Biosciences (NASDAQ:ARTL) shares increased by 12.69% to $1.42. The market value of their outstanding shares is at $4.0
The combined company will operate as "Gyre Therapeutics, Inc." with its common stock traded on Nasdaq under trading symbol "GYRE" effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst") today announced completion of the business combination with GNI Group Ltd. and related entities. Catalyst received stockholder approval for all proposals necessary to complete the business combination at a special meeting of stockholders held on August 29, 2023. Catalyst effected a name change and a reverse stock split of Catalyst's common stock immediately prior to the closing of the business combination. The combined company will
Gainers Abri SPAC I, Inc. (NASDAQ:ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. Nuvve Holding Corp. (NASDAQ:NVVE) shares climbed 88% to $0.2789 after falling 10% on Tuesday. Nuvve recently announced pricing of a $1 million underwritten public offering of roughly 7 million shares of common stock at a price to the public of $0.14 per share. BIO-key International, Inc. (NASDAQ:BKYI) surged 57% to $0.30. BIO-key International reported results for its third quarter ended Sept. 30, 2023. ReShape Lifesciences Inc. (NASDAQ:RSLS) gained 44.7% to $0.2976 after gaining over 6% on Tuesday. ReShape Lifesciences recently announced p
Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares rose 30.0% to $2.34 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of 1.4 million shares, making up 4222.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $83.4 million. Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 24.06% to $0.26. Trading volume for this security as of 13:30 EST is 46.7 million, which is 2583.2% of its average full-day volume over the last 100 days. The company's market cap stands at $1.3 million. BioXcel Therapeutics (NASDAQ:BTAI) shares rose 17.94% to $2.76. The current volume of 63.0 million shares is 460
Gainers INVO Bioscience, Inc. (NASDAQ:INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction. LumiraDx Limited (NASDAQ:LMDX) shares climbed 187.4% to $0.25 after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub. Akumin Inc. (NASDAQ:AKU) shares climbed 125% to $0.3279 after the company reached an agreement with Stonepeak to become a private company. Textainer Group Holdings Limited (NYSE:TGH) shares gained 44.5% to $49.33 after the company agreed to be acquired by Stonepeak for $7.4 billion. Twin Ridge Capital Acquisition Co
Gainers LumiraDx (NASDAQ:LMDX) shares increased by 281.2% to $0.34 during Monday's pre-market session. The company's market cap stands at $108.5 million. INVO Bioscience (NASDAQ:INVO) stock rose 185.18% to $1.54. The market value of their outstanding shares is at $3.7 million. Apollomics (NASDAQ:APLM) stock moved upwards by 33.71% to $2.34. The company's market cap stands at $209.3 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock increased by 14.8% to $0.42. The company's market cap stands at $3.4 million. AcelRx Pharmaceuticals (NASDAQ:ACRX) stock moved upwards by 12.39% to $0.63. The company's market cap stands at $10.2 million. SomaLogic (NASDAQ:SLGC) stock rose 12.0% to $2.52. T
Gainers LumiraDx Limited (NASDAQ:LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub. Akumin Inc. (NASDAQ:AKU) shares rose 56.6% to $0.2285 in pre-market trading after the company reached an agreement with Stonepeak to become a private company. Next.e.GO N.V. (NASDAQ:EGOX) rose 47.5% to $2.08 in pre-market trading. Next.e.GO Mobile and Athena Consumer Acquisition announced the completion of their previously announced business combination. Textainer Group Holdings Limited (NYSE:TGH) shares gained 42.6% to $48.69
Gainers XORTX Therapeutics Inc. (NASDAQ:XRTX) shares jumped 60.2% to $0.5101 after jumping 34% on Thursday. Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) climbed 58.7% to $2.46. Lipella Pharmaceuticals announced FDA clearance of IND for LP-310 for oral lichen planus. Catalyst Biosciences, Inc. (NASDAQ:CBIO) jumped 44% to $0.5780. MMTec, Inc. (NASDAQ:MTC) gained 37.6% to $2.84 after jumping 51% on Thursday. MMTEC is scheduled to hold its 2023 annual meeting of shareholders on Nov. 10, 2023. Nouveau Monde Graphite Inc. (NYSE:NMG) surged 28% to $2.60 Aravive, Inc. (NASDAQ:ARAV) shares climbed 26.3% to $0.1780 after falling 15% on Thursday. HUB Cyber Security Ltd. (NASDAQ:HUBC) shares ju
Gainers Aravive (NASDAQ:ARAV) shares rose 67.5% to $0.24 during Friday's regular session. As of 13:30 EST, this security is trading at a volume of 90.0 million shares, making up 979.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $17.3 million. Lipella Pharmaceuticals (NASDAQ:LIPO) stock moved upwards by 42.27% to $2.29. Lipella Pharmaceuticals's stock is trading at a volume of 39.3 million shares as of 13:30 EST. This is 574673.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.2 million. Sagimet Biosciences (NASDAQ:SGMT) shares rose 25.27% to $5.72. As of 13:30 EST,
Gainers MingZhu Logistics Holdings Limited (NASDAQ:YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. PCTEL, Inc. (NASDAQ:PCTI) climbed 47.3% to $6.86. On Friday, Amphenol Corp (NYSE:APH) inked a deal to acquire PCTEL for around $139.7 million. Almacenes Éxito S.A. (NYSE:EXTO) shares rose 32.6% to $6.66. MMTec, Inc. (NASDAQ:MTC) surged 30% to $0.7608. Tempest Therapeutics, Inc. (NASDAQ:TPST) gained 29% to $4.72. LQR House Inc. (NASDAQ:LQR) shares climbed 24.5% to $0.2148. LQR House announced that through its custom marketing campaign and strategic efforts, Von Payne Whiskey is now displayed on the shelves of the retail giant, Costco. Secoo Holding Limited (N